Biden promised to turn the page on Trump. Now he's being replaced by him
Firefighters prepare for increasing gusts following brief reprieve for LA area
John Ratcliffe, tapped by Trump to lead the CIA, will face questioning in the Senate
Nippon Steel wants to work with Trump administration on US Steel deal, Mori tells WSJ
After cable damage, Taiwan to step up surveillance of flag of convenience ships
BOJ will raise rates if economy, price conditions continue to improve, Ueda says
Manatees congregate in warm waters near power plants as US winter storms graze Florida
AAPI adults prioritize immigration, but split on mass deportations: AP-NORC/AAPI Data poll
As Los Angeles burns, Hollywood's Oscar season turns into a pledge drive
As fires ravage Los Angeles, Tiger Woods isn't sure what will happen with Riviera tournament
Antetokounmpo gets 50th career triple-double as Bucks win 130-115 to end Kings' 7-game win streak
(Reuters) -Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant for use in infants, children and adults.
The Medicines and Healthcare products Regulatory Agency (MHRA) said it has approved four forms of the adapted Comirnaty JN.1 vaccine after reviewing its safety, quality and effectiveness.
The regulator also said it would keep the safety of the vaccine under close review.
Globally, regulators like the European Medicines Agency and the World Health Organisation are recommending that COVID vaccine manufacturers update their vaccines to target the JN.1 variant, although the U.S. Food and Drug Administration suggested the targeting of the newer KP.2 variant, if feasible.
(Reporting by Unnamalai L in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber)
